IDH1 and neoplasm: The WHO molecular subgrouping into IDH-wild-type and IDH-mutant glioblastoma emphasizes a significantly longer survival for the IDH-mutant subgroup, due to a slower tumor growth rate, and reflected in a more insidious onset [4].